Skip to main content
Isomer
  1. Home
  2. Automated
  3. List of product information
  4. FUGACIN TABLET 200 MG [SIN08409P]

FUGACIN TABLET 200 MG [SIN08409P]

Active ingredients: FUGACIN TABLET 200 MG

Last updated 26 October 2025

Product Info

FUGACIN TABLET 200 MG

[SIN08409P]

Product information

Active Ingredient and Strength

OFLOXACIN - 200 MG

Dosage Form

TABLET, FILM COATED

Manufacturer and Country

SHIN POONG PHARMACEUTICAL CO LTD - KOREA, REPUBLIC OF

Registration Number

SIN08409P

Licence Holder

ZYFAS PHARMA PTE LTD

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

J01MA01

[INDICATIONS]
The following infections caused by ofloxacin-susceptible Staphylococcus sp., Streptococcus pyogenes, hemolytic streptococci, enterococci, Streptococcus pneumoniae, peptostreptococcus sp., Escherichia coli, Citrobacter sp., Shigella sp., Klebsiella pneumoniae, Enterobacter sp., Serratia sp., Proteus sp., Pseudomonas aeruginosa, Haemophilus influenzae, Acinetobacter sp., and Campylobacter sp.

  • Folliculitis, furuncle, furunculosis, carbuncle, erysipelas, phlegmon, lymphangitis (lymphadenitis)

  • Felon, subcutaneous abscess, spiradenitis, acne conglobata, infectious atheroma, perianal abscess

  • Mastadenitis, superficial secondary infections after traumas, burns, surgery traumas

  • Pharyngolaryngitis, acute bronchitis, tonsillitis, chronic bronchitis, diffuse panbronchiolitis, bronchiectasis with infection, secondary infections of chronic respiratory diseases, pneumonia

  • Pyelonephritis, cystitis, prostatitis, epididymitis, gonococcal urethritis, non-gonococcal urethritis

  • Cholecystitis, cholangitis, bacillary dysentery, enteritis

  • Intrauterine infection, adnexitis, bartholinitis

  • Blepharitis, hordeolum, dacryocystitis, tarsadentitis, keratohelcosis

  • Otitis media, sinusitis

[DOSAGE AND ADMINISTRATION]
FUGACIN is generally given to adults orally in a daily dose of 1.5–3 tablets (300–600mg) divided into 2 to 3 times.
Dosage may be adjusted according to causative organisms and severity of symptoms.
Overdose: In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation.

  1. Contraindication
    Patients with a history of hypersensitivity to ofloxacin.

  2. Careful administration

    1. Patients with severe renal disorders

    2. Patients with or with a history of convulsive diseases such as epilepsy.

    3. Patients with a history of hypersensitivity to quinolones.

    4. The elderly patients